Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this project is to examine the cardiac symptoms and physiologic changes after administration of a reduced dose of carbetocin in participants undergoing elective cesarian section.
Participants will:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 50mcg of Carbetocin | Experimental | Participants in this arm will receive 50mcg of carbetocin for post party hemorrhage prophylaxis at the the time of umbilical cord clamping during their cesarian section. |
|
| 100mcg of Carbetocin | Active Comparator | Participants in this arm will receive 100mcg of carbetocin for post party hemorrhage prophylaxis at the the time of umbilical cord clamping during their cesarian section. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Carbetocin | Drug | A uterotonic agent used for the prevention of postpartum hemorrhage in Cesarian section |
|
| Measure | Description | Time Frame |
|---|---|---|
| Patient reported symptoms | Subjective patient reported symptoms of cardiac ischemia, reported with descriptive words | within 5 minutes of study drug administration |
| Measure | Description | Time Frame |
|---|---|---|
| Troponin I levels | Troponin I levels on blood work | One day after study drug administration |
| ECG: ST segment | Changes to the ST segment on ECG |
| Measure | Description | Time Frame |
|---|---|---|
| Estimated blood loss during surgery | Recorded from anesthesiologists assessment | Within 1 hour of study drug administration |
| Surgeons assessment of uterine tone | Assessed as a binary of adequate or not adequate |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jordan Leitch, MD | Contact | 613-549-6666 | jordan.leitch@kingstonhsc.ca | |
| Taylor Perry, MD | Contact | (613) 548-3232 | taylorchristina.perry@kingstonHSC.ca |
| Name | Affiliation | Role |
|---|---|---|
| Jordan Leitch, MD | Queen's University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kingston Health Sciences Centre | Kingston | Ontario | K7L 2V7 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C020731 | carbetocin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 5 minutes after study drug administration |
| 3 minutes after study drug administration |
| Hemoglobin change | Assessed as a difference between preoperative and postoperative hemoglobin | Preoperatively and one day postoperatively |
| D001161 |
| Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |